AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that it has completed patient enrollment in the two remaining Phase 3 studies of ARX-04:. Pamela Palmer, AcelRx's chief medical officer and co-found
Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it has completed patient enrollment in the Phase 3 TACTT3 clinical trial with Keyzilen TM in acute and post-acute inner ear tinnitus. "Our Phase 3 clinical trial program for Ke
Researchers are reporting that early rapid improvements in the signs and symptoms of axial spondyloarthritis in patients treated with certolizumab pegol are maintained at 4 years. Desiree van der Heijde, with Leiden University Medical Centre in the Netherlands, and colleagues elsewhere examined outcomes at week 204 in patients who were randomized t
-Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, has been added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes, as part of the Russell US Indexes annual reconstitution, effective after the US market opens on June 27.
TEL AVIV, Israel, June 28, 2016/ PRNewswire/ BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions required to commence a Phase 2 a trial for BL-8040 in combination with KEYTRUDA for the treatment of
By a News Reporter-Staff News Editor at World Disease Weekly The biopharmaceutical company Celgene has become the fifth company to join the "Neglected Tropical Diseases Drug Discovery Booster" consortium, a new initiative to accelerate and cut the cost of early stage drug discovery for two of the world's most neglected diseases, leishmaniasis and
Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the completion of its submission of the MAA for solithromycin to the European Medicines Agency for the treatment of community-acquired bacterial pneumonia.
Cure Forward, an online precision medicine platform for cancer patients and their care teams, and Novartis Pharmaceuticals Corporation today announced that Cure Forward s unique Clinical Trial Exchange will support Novartis in identifying potential patients for all of its current oncology trials. The collaboration further validates Cure Forward
-The United States FDA recently approved the use of the dermal filler, Volbella, starting in October of 2016, according to Yahoo Finance. Volbella is a great addition to the dermal filler family, said Dr. Kulbersh. With the media exposure of reality stars like Kylie Jenner to musician Iggy Azalea undergoing lip injection procedures, the popularity
-Emergent BioSolutions Inc. today announced that its Center for Innovation in Advanced Development and Manufacturing has received a task order from the Biomedical Advanced Research and Development Authority valued at up to $21.9 million to develop and manufacture three cGMP lots of a Zika vaccine for use in a Phase 1 clinical trial. The task order
Genentech, a member of the Roche Group announced today that the U.S. Food and Drug Administration accepted for review the company s Biologics License Application for OCREVUS? for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis, and granted the application Priority Review Designation with a targeted acti
Genentech, a member of the Roche Group announced today that the U.S. Food and Drug Administration accepted for review the companys Biologics License Application for OCREVUS for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis, and granted the application Priority Review Designation with a targeted action date
SOUTH SAN FRANCISCO- Genentech, a member of the Roche Group, said that the U.S. Food and Drug Administration or FDA accepted for review the company's Biologics License Application or BLA for OCREVUS for the treatment of relapsing multiple sclerosis or RMS and primary progressive multiple sclerosis or PPMS, and granted the application Priority Revie
GlycoMimetics, Inc. today announced dosing of the first patient with newly diagnosed acute myeloid leukemia in the Phase 2 portion of its ongoing Phase 1/ 2 study evaluating its novel E-selectin antagonist, GMI-1271, combined with chemotherapy. In addition, GlycoMimetics recently announced that the first patient with relapsed or refractory AML has
Release date- 27062016- Hyundai Heavy Industries, the world's largest shipbuilder and a leading medical robot manufacturer, announced today it is successfully testing three types of its proprietary medical robots at Asan Medical Center, Ulsan University Hospital, Chonnam National University Gwangju 2nd Geriatric Hospital and Ulsan Noin Hospital.
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced that, following communication with the U.S. Food and Drug Administration, the Company has initiated Phase 3 development of ITI-007 for the treatment of agitation in patients with dementia,...
JDP Therapeutics Inc., a privately held late stage specialty pharmaceutical company, today announced that it has secured up to $17 million Series A equity financing led by China based CoSci Med-Tech Co., Ltd.. Prior to this round of financing, JDP-205 had successfully completed phase I and II clinical trials, an end-of-phase-II FDA meeting, and FDA
Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Diazepam Oral Solution, 5 mg/5 mL, the therapeutic equivalent to the reference listed drug, Diazepam Oral Solution, 5 mg/5 mL, of Roxane Laboratories, Inc. According to IMS, total U.S. sales in
NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced that topline results from Trial 005, a pilot, dose-finding pharmacokinetic study on healthy subjects, demonstrate that ND0612H, the company s continuous, subcutaneously delivered levodopa/carbidopa liquid formulation,.
Maxwell Biotech Venture Fund's portfolio company NeuroMax Ltd and its development partner, Aquilus Pharmaceuticals, Inc today announced the start of Phase 1, open label, prospective, safety, tolerability and pharmacokinetics study of AQU-005 for the treatment of chronic neuropathic pain. We are planning to start proof of concept clinical trials in.
-Parallel 6, the leading software as a service provider of mClinical solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the patient and their care circle with the physician and clinical trial team. The Clinical Reach CONSULT
By a News Reporter-Staff News Editor at Cancer Weekly From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Frost, Philip; Liao, William W. N.; Rowinsky, Eric K., filed on August 25, 2011, was published online on June 14, 2016. The patent's assignee for patent number 9364479 is SYMPHONY EVOLUTION, INC.. News editors
PhytoPain Pharma Inc., a subsidiary of GrowPros Cannabis Ventures Inc., is pleased to announce a successful pre-CTA consultation with the Therapeutic Products Directorate of Health Canada regarding its proposed Phase I clinical study of smoked cannabis. Health Canada provided feedback and guidance on the Phase I trial's study population, placebo...
Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced top-line data from a Phase 2 exploratory, investigator-sponsored study to evaluate the safety, tolerability and efficacy of ganaxolone for the treatment of anxiety and
By a News Reporter-Staff News Editor at China Weekly News Sirona Biochem Corp. announced that Wanbang Biopharmaceuticals has confirmed they will be proceeding with studies to prepare for Investigational New Drug filing for the anti-diabetic SGLT2 Inhibitor, SBM-TFC-039. Sirona Biochem has received a milestone payment of US$ 300,000 from Wanbang..